What FHC Group does

FHC Group (legal name: FHC – Farmacêutica, S.A.) is a privately-held Portuguese pharmaceutical conglomerate founded in February 1998 and headquartered in Mortágua, Portugal. The group operates 13 wholly-owned subsidiaries spanning the full pharmaceutical value chain, including clinical research and biotech (Basinnov), pharmaceutical manufacturing (Laboratórios Basi with Eudra GMP-certified injectables facility producing 200+ medicines, and Laphysan in Spain), B2B distribution to hospitals and pharmacies (Overpharma, Empifarma with Knapp robotic logistics, Mozpharma, Socifarma, Worldrugs, SVP Pharma UK), retail pharmacy operations (Mecofarma's 19-store chain in Angola), and IT consulting and proprietary B2B software (Zeone Consulting, ePharma, Magium Farma). The group employs 820 people and reported aggregate turnover of €543M, EBITDA of €24M, and equity of €231M as of 2025 financial indicators.

FHC generates revenue through five principal streams: pharmaceutical manufacturing and sales (Basi and Laphysan brands), B2B distribution and logistics services (Empifarma and Overpharma channel partners to pharmacies and hospitals), retail pharmacy transactions (Mecofarma consumer-facing operations in Angola), international export and licensing across 65 countries (FHC | Farmacêutica global commercialization), and IT consulting and software services (Zeone and ePharma). Its go-to-market is sales-led, relying on direct enterprise sales teams for hospital and pharmaceutical manufacturer accounts, automated channel distribution for retail pharmacies, and licensing/partnership structures for international expansion. The group holds ISO 9001, 14001, 45001, and 50001 certifications at Laboratórios Basi and serves markets across 4 continents (Europe, Africa, Americas, Asia) with direct presence in 8 geographies.

The conglomerate's competitive position rests on a combination of regulatory authorizations (Eudra GMP for injectables), automated logistics infrastructure (Knapp robotic warehouses with 9,000m² coverage), a 25-year track record of pharmaceutical operations under private Portuguese capital, and an integrated value chain from R&D through retail. Recent strategic direction emphasizes biotechnology innovation (Basinnov, TargTex investment, Basi Innov.Bio.Tech program), geographic expansion into English-speaking and African markets (SVP Pharma UK, Guinepharma, Mozpharma), and inorganic growth through acquisition of distribution and retail pharmacy assets in Lusophone markets.

Name

FHC Group

Legal name

FHC – Farmacêutica, S.A.

Website

https://fhcthefutureofhealthcare.pt

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Short description

FHC Group is a privately-held Portuguese pharmaceutical conglomerate operating 13 subsidiaries across the full pharmaceutical value chain, including manufacturing, distribution, retail pharmacy, biotech R&D, and IT consulting, serving 65 countries with €543M revenue and 820 employees.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution and Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Pharmaceutical distribution
• Pharmaceutical manufacturing
• Hospital supply services
• Retail pharmacy network
• Biotechnology research

Headquarters

HQ city

Mortágua

HQ country

Portugal

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Manufacturing and Sales: Revenue from manufacturing and selling pharmaceutical products through Laboratórios Basi, Laphysan, and other manufacturing entities - produces over 200 medicines in portfolio
2. Distribution and Logistics Services: Revenue from pharmaceutical distribution services through Empifarma, Overpharma, Mozpharma, Socifarma, Worldrugs serving pharmacies, hospitals, and pharmaceutical industry clients
3. Retail Pharmacy Operations: Revenue from retail pharmacy chain operations through Mecofarma in Angola (19 pharmacies and 2 pet shops)
4. International Export and Licensing: Revenue from export, registration and licensing activities across 65 countries, including manufacturing contract arrangements
5. Technology and Consulting Services: Revenue from IT consulting services through Zeone Consulting and technology solutions through ePharma

Go-to-market motion1 record

Distribution channels8 records

Marketing channels6 records

Core offering

FHC Group is a Portuguese private pharmaceutical conglomerate that manufactures, distributes, and retails medicines across 65+ countries. It operates the full pharmaceutical value chain through subsidiaries covering clinical research in oncology (Basinnov), Eudra GMP-certified injectable manufacturing (Laboratórios Basi in Portugal, Laphysan in Spain), automated wholesale distribution to pharmacies and hospitals (Empifarma, Overpharma, Worldrugs), international commercialization (FHC | Farmacêutica), retail pharmacy (Mecofarma in Angola with 19 pharmacies and 2 pet shops), and IT consulting and healthcare technology services (Zeone Consulting, ePharma, Magium Farma B2B software).

Product overview

FHC Group operates as a diversified pharmaceutical conglomerate with a portfolio of 13 subsidiary companies spanning the entire medicine value chain. The group offers a unified ecosystem of pharmaceutical services including clinical research (Basinnov), technology innovation (ePharma, Zeone Consulting), manufacturing (Laboratórios Basi with Eudra GMP-certified injectables facility, Laphysan), logistics and distribution (Empifarma with Knapp robotized warehouses, Mozpharma, Overpharma, Socifarma, Worldrugs, SVP Pharma), and retail pharmacy (Mecofarma). The group also provides international commercialization and distribution services through FHC | Farmacêutica, its holding company. Key products include over 200 medicines manufactured by Laboratórios Basi, pharmaceutical logistics software (Magium Farma B2B), and therapeutic solutions across oncology, immunotherapy, fluidotherapy, anesthesia, cardiology, urology, and wound care. The group serves markets across 4 continents in 65+ countries through direct presence in 8 geographies (Portugal, Spain, France, UK, Angola, Mozambique, South Africa, Brazil) and exported products worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Basinnov: Life sciences and biotechnology company seeking and developing disruptive therapeutic solutions in oncology and immunotherapy, founded 2020
• Empifarma
• ePharma
• Laboratórios Basi
• Laphysan
• Overpharma
• Zeone Consulting

Products and services

• Laboratórios Basi - Pharmaceutical Contract Manufacturing Manufacturer of small and large volume injectable pharmaceuticals at an Eudra GMP-certified facility in Mortágua, Portugal; develops, manufactures, markets and distributes 200+ medicines globally under European quality standards.
• Empifarma - Outpatient Pharmaceutical Distribution Full-liner pharmaceutical distributor in Portugal operating two highly automated Knapp robotic logistics units, serving pharmacies, para-pharmacies, and the pharmaceutical industry in the ambulatory market.
• Overpharma - Hospital Pharmaceutical Distribution Commercialization of high-quality hospital medical products in Portugal including medicines, medical devices, and hygiene products for healthcare professionals in the hospital market.
• FHC | Farmacêutica - International Pharmaceutical Commercialization International commercialization and distribution of healthcare products across 65+ countries through licensing, registration, export, and contract manufacturing arrangements.
• Laphysan - Pharmaceutical Manufacturing (Spain) Pharmaceutical manufacturer operating in the Spanish hospital sector, providing therapeutic solutions in fluidotherapy, anesthesia, cardiology, urology, wounds, and disinfection with full peninsular and island coverage.
• Mozpharma - Pharmaceutical Distribution (Mozambique) Importer and distributor of healthcare products operating in the Mozambican pharmaceutical market, providing cost-effective health products to millions of Mozambicans through deep sector knowledge and an extensive local network.
• Mecofarma - Retail Pharmacy Network (Angola) Angola's oldest pharmacy chain, operating 19 pharmacies and 2 pet shops to provide retail pharmacy services, pharmaceutical care, and health promotion to the Angolan population.
• SVP Pharma - UK Pharmaceutical Distribution Distribution of Laboratórios Basi medicines in the United Kingdom, providing British-market access to Portuguese-manufactured pharmaceutical products with experienced professionals and deep sector knowledge.
• Worldrugs - Portugal Pharmaceutical Logistics Portuguese pharmaceutical logistics company with 10+ years of presence providing multidisciplinary, integrated logistics services between industry and wholesalers in the Portuguese pharmaceutical channel.
• Basinnov - Clinical Research in Oncology and Immunotherapy Life sciences company researching and developing disruptive therapeutic solutions in oncology and immunotherapy, including the Basi Innov.Bio.Tech open-innovation program targeting startups worldwide.
• Zeone Consulting - Pharmaceutical IT Consulting Services IT services and consultancy with vertical team specialization in the pharmaceutical sector, providing process redesign, optimization, and new-technology consulting for pharmaceutical clients.
• ePharma - Healthcare Technology Solutions Technology-solutions provider for the pharmaceutical market, enabling clients to be more efficient through innovative technology features and advanced capabilities delivering high-impact business solutions.
• Magium Farma B2B Software B2B electronic ordering and commerce platform developed by Zeone for the pharmaceutical distribution channel, enabling pharmacies to place orders and manage supply chain operations.

Quantifiable outcome

• Pharmaceutical products available to millions of people in 65+ countries at affordable costs
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor, core and strategic.

• Gonçalo BernardesminorOthers · 14 March 2023Basinnov hired Gonçalo Bernardes as Scientific Advisor. He brings extensive experience in oncology and immunotherapy research, having been Professor of Chemical Biology at Cambridge University, and is co-founder of TargTex (co-invested by Basi).
• Beta-icoreStrategic or Co-development Partner · 8 March 2022Collaborative innovation partnership for the Basi Innov.Bio.Tech open innovation program targeting oncology and immunotherapy startups globally. Beta-i provides technical management for selecting and managing pilot projects with startups worldwide, selecting up to 15 projects for exploratory talks and 5 for Collaboration Design Sprint, ultimately selecting 2 startups for joint solution development.
• TargTexcoreStrategic or Co-development Partner · 1 January 2022Strategic investment and partnership with TargTex, a private biotech company developing an innovative new treatment for Glioblastoma Multiforme (GBM), the most aggressive type of brain tumor. Basi invested in TargTex in 2022 as part of its oncology strategy.
• iBET - Instituto de Biologia Experimental e TecnológicastrategicStrategic or Co-development Partner · 1 January 2020Laboratórios Basi became an associate of iBET, enabling access to cutting-edge research in biological and experimental technology, supporting R&D activities in the pharmaceutical sector.

Scale indicators12 records

Recent moves13 records

Expansion highlights5 records

Direct peers

• Stada Arzneimittel: European-focused generics manufacturer with branded products, biosimilars, and consumer health. Directly comparable to FHC's Laboratórios Basi and Laphysan subsidiaries on the manufacturing side, and shares the European-mid-size private/group ownership profile (taken private in 2017).
• Almirall: Spanish pharmaceutical company focused on dermatology and specialty medicines with European manufacturing and distribution. Comparable as a mid-size Iberian pharma group with branded manufacturing and European commercial reach.
• Hikma Pharmaceuticals: UK-listed (FTSE 250) pharmaceutical group with a strong injectables franchise (Hikma Injectables) and MENA distribution operations. Directly comparable to FHC's combination of Eudra GMP injectable manufacturing and emerging-market distribution/retail exposure.
• Aspen Pharmacare: South African pharmaceutical manufacturer and distributor with global footprint spanning emerging markets and Europe. Comparable to FHC's combination of African distribution/retail (Mozpharma, Socifarma, Mecofarma) plus European-origin manufacturing.
• Faes Farma: Spanish pharmaceutical company with manufacturing, licensing, and distribution across Iberia and Latin America. Comparable to FHC in scope (manufacturing + international distribution) and Iberian geographic base, with a similar mid-cap profile.
• Laboratorios Rovi: Spanish pharmaceutical manufacturer specializing in injectable drugs, prefilled syringes, and hospital distribution — closely mirroring Laboratórios Basi's injectable focus and Laphysan's Spanish-market positioning. Both are mid-size Iberian pharma groups with hospital-channel emphasis.

Broad incumbents

• B. Braun: German family-owned medical and pharmaceutical company with global manufacturing of injectables, infusion solutions, and pharmaceutical distribution. Comparable to FHC as a privately-held, vertically integrated European pharma/med-device conglomerate with Eudra GMP manufacturing and worldwide distribution.
• Alliance Healthcare (Walgreens Boots Alliance): Pharmaceutical wholesaler and pre-wholesaler operating across Europe, owned by Walgreens Boots Alliance. Direct functional comparable to Empifarma and Overpharma's wholesale business, with similar B2B pharmacy and hospital distribution model.
• Phoenix Group: Europe's largest pharmaceutical wholesaler with pan-European distribution and retail pharmacy networks (including BENU). Comparable to Empifarma/Overpharma's wholesale operations but at vastly greater scale, representing the structural competitive threat.
• Celesio/McKesson Europe: European pharmaceutical distribution and services business owned by McKesson, operating wholesale, retail pharmacy, and patient services. Most direct functional competitor to Empifarma/Overpharma at significantly greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCBcsCX2y_ky31fGsQwzB-gg
• Facebookfacebook.com/fhcthefutureofhealthcare
• LinkedInlinkedin.com/company/fhc-group
• Instagraminstagram.com/fhcthefutureofhealthcare

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FHC Group